English Svenska Deutsch Suomi Zenicor-ECG News Research About Zenicor Contact Zenicor Zenicor-ECG Use cases Customer references Patient cases Product information Research reports Arrhythmia investigations Primary stroke prevention Secondary stroke prevention Cost-effectiveness List of references News Calendar About Zenicor Medical background Zenicor today The history of Zenicor Board of Directors Job vacancies Press material Contact Contact form Site map Zenicor Zenicor-ECG Use cases Customer references Patient cases Product information Research reports Arrhythmia investigations Primary stroke prevention Secondary stroke prevention Cost-effectiveness List of references News Calendar About Zenicor Medical background Zenicor today The history of Zenicor Board of Directors Job vacancies Press material Contact Contact form Site map Use cases Spotting AF, Stopping stroke Patients who have had a stroke/TIA or who have a CHADS2 score of at least two are provided with a Zenicor-ECG to take regular ECGs twice a day for four weeks. Studies show that Zenicor-ECG identifies previously undiagnosed silent atrial fibrillation in up to 13% of patients. Every day 20 people in Sweden have a stroke due to undiagnosed or untreated atrial fibrillation. This causes great suffering and costs Swedish healthcare several billion kronor each year. Zenicor-ECG can identify these atrial fibrillations and with the correct treatment, a large number of strokes can be prevented Three times more effective than Holter Patients suffering from symptoms of an irregular heart rhythm, e.g. palpitations, dizziness or fibrillation borrow a Zenicor-ECG from the hospital. When the patient experiences symptoms, they press start on the device, then place their thumbs on the electrodes. When the reading has been taken, the patient sends the ECG reading to a central ECG database at the touch of a button. The patient’s readings are stored in the database and the doctor can simply determine what the patient is suffering from. Studies show that this method of detecting paroxysmal intermittent cardiac arrhythmia is three times more effective than Holter-ECG, the most common method of diagnosing arrhythmia today. Zenicor-ECG used at paediatric cardiology clinics Zenicor-ECG is currently used at more than 50 paediatric cardiology clinics in the Nordic region and Germany. The advantage of Zenicor-ECG is its simplicity. No fixed chest electrodes need to be operated in. The patient can easily take Zenicor-ECG with them to school or sports activities. After a hospital visit, the patient takes the device home with them for as long an investigation period as is necessary – sometimes several months. The likelihood of detecting arrhythmia increases significantly when the length of the investigation period can be extended. Arrhythmia investigation easier than ever Up to half of patients may only feel the effects of their arrhythmia after one to three weeks, which is why Zenicor-ECG is a uniquely effective method. The simplicity and convenience for the patient means that the investigation can be performed over a longer period. A clinically verified method with proven efficacy and simplicity. © Zenicor Medical Systems AB News archive · Site map · Information about cookies · Publisher responsible · Follow us on ·